Supplementary figures from Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma

Supplementary Fig. S1. The mean baseline Levels of PIP3 (38:4) per mg tissue in xenograft models transplanted with SCLC cells Supplementary Fig. S2. Metabolic alteration in SCLC cells treated with gedatolisib in vitro and in vivo Supplementary Fig. S3. Comparative metabolic profiling in LAD and SCLC cell lines Supplementary Fig. S4. Gene expression alteration after treatment with PI3K/mTOR inhibitor Supplementary Fig. S5. Schematic diagram of metabolic linkage Supplementary Fig. S6. Addition of 5''-deoxy-5''-(methylthio)-adenosine (MTA) reversed drug sensitivity from a resistant to a sensitive phenotype Supplementary Fig. S7. HPRT1 expression was downregulated by an HPRT1-specific siRNA in SCLC cells